Form 4: Kiniksa Pharmaceuticals Executive Ross Moat Executes Stock Option Plan, Sells Shares

Chief Commercial Officer Ross Moat exercised stock options and sold shares of Kiniksa Pharmaceuticals International, plc, according to a recent SEC Form 4 filing.

Summary

• Ross Moat, Chief Commercial Officer of Kiniksa Pharmaceuticals International, plc, executed transactions involving Class A Ordinary Shares.
• On April 29, 2025, Moat exercised share options to acquire a total of 64,035 shares at prices ranging from $10.76 to $15.52.
• On the same day, Moat sold 64,035 shares at a weighted average price of $25.21.
• On May 1, 2025, Moat exercised share options to acquire a total of 23,234 shares at prices ranging from $11.10 to $17.76.
• On the same day, Moat sold 23,234 shares at a weighted average price of $28.02.
• These transactions were conducted under a pre-arranged 10b5-1 trading plan adopted on May 3, 2024.
• Following these transactions, Moat directly owns 9,415 Class A Ordinary Shares.
• Moat also holds options to acquire 171,856 Class A Ordinary Shares at various exercise prices and expiration dates.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting transactions. The fact that the sales are pre-planned under a 10b5-1 plan suggests no immediate cause for concern, but the sales themselves don't necessarily indicate strong positive sentiment either.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, although the pre-planned nature of these sales mitigates this risk.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance.

Industry Context

Executive stock transactions are common in publicly traded companies and are often part of their compensation packages. Monitoring these transactions can provide insights into management's perspective on the company's value.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical industry often include stock options to align management's interests with those of shareholders.
• The use of 10b5-1 trading plans is a standard practice to allow insiders to sell shares without raising concerns about insider trading.
• Comparing the size and frequency of these transactions with those of executives at similar-sized pharmaceutical companies can provide a benchmark for assessing the significance of these sales.

Stakeholder Impact

• Shareholders may be interested in these transactions as they provide insight into executive behavior.
• The transactions themselves are unlikely to have a significant impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Kiniksa Pharmaceuticals, Ross Moat, stock options, SEC Form 4, insider trading, Class A Ordinary Shares, 10b5-1 plan, executive compensation